These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
126 related articles for article (PubMed ID: 752871)
1. Results of a nonrandomized trial in malignant melanoma patients (Clark's stages III--V) treated by post-surgical chemoimmunotherapy. Serrou B; Pujol H; Domas J; Gauci L Recent Results Cancer Res; 1978; 68():363-6. PubMed ID: 752871 [No Abstract] [Full Text] [Related]
2. Adjuvant chemotherapy or chemoimmunotherapy in the management of primary malignant melanoma of level III, IV, or V. Jacquillat C; Banzet P; Civatte J; Puissant A; Cottenot F; Israel L; Belaich S; Chastang C; Maral J Recent Results Cancer Res; 1978; 68():346-58. PubMed ID: 111323 [No Abstract] [Full Text] [Related]
3. Chemoimmunotherapy with bleomycin, vincristine, lomustine, dacarbazine (BOLD) plus interferon alpha for metastatic melanoma: a multicentre phase II study. Punt CJ; van Herpen CM; Jansen RL; Vreugdenhil G; Muller EW; de Mulder PH Br J Cancer; 1997; 76(2):266-9. PubMed ID: 9231931 [TBL] [Abstract][Full Text] [Related]
4. Chemoimmunotherapy for metastatic malignant melanoma using vincristine (NSC-67574), DTIC (NSC-45388) and Bacillus Calmette-Guerin. Thatcher N; Blackledge G; Palmer MK; Crowther D Eur J Cancer (1965); 1981 Apr; 17(4):465-9. PubMed ID: 7308256 [No Abstract] [Full Text] [Related]
5. Chemotherapy of malignant melanoma. Benjamin RS World J Surg; 1979 Jul; 3(3):321-8. PubMed ID: 382646 [No Abstract] [Full Text] [Related]
6. Bacillus Calmette-Guérin immunotherapy in combination with DTIC (NSC-45388) for the treatment of malignant melanoma. Gutterman JU; Mavligit GM; Reed R; Burgess MA; Gottlieb J; Hersh EM Cancer Treat Rep; 1976 Feb; 60(2):177-82. PubMed ID: 769970 [TBL] [Abstract][Full Text] [Related]
7. Randomized controlled trial of adjuvant chemoimmunotherapy with DTIC and BCG after complete excision of primary melanoma with a poor prognosis or melanoma metastases. Can Med Assoc J; 1983 Apr; 128(8):929-33. PubMed ID: 6339024 [TBL] [Abstract][Full Text] [Related]
8. [Experience with adjuvant chemoimmunotherapy with DTIC and BCG in malignant melanoma (author's transl)]. Pullmann H; Muth M Z Hautkr; 1982 Feb; 57(4):294-7. PubMed ID: 7080583 [No Abstract] [Full Text] [Related]
9. Chemoimmunotherapy of disseminated malignant melanoma with dimethyl triazeno imidazole carboxamide and bacillus calmette--guérin. Gutterman JU; Mavligit G; Gottlieb JA; Burgess MA; McBride CE; Einhorn L; Freireich EJ; Hersh EM N Engl J Med; 1974 Sep; 291(12):592-7. PubMed ID: 4851001 [No Abstract] [Full Text] [Related]
10. Combined modality therapy of malignant melanoma. Hersh EM; Gutterman JU; McBride CM World J Surg; 1979 Jul; 3(3):329-43. PubMed ID: 382647 [No Abstract] [Full Text] [Related]
11. Single drug and combination chemotherapy in the treatment. Disseminated malignant melanoma. Aranha GV; Grage TB Minn Med; 1977 Aug; 60(8):543-8. PubMed ID: 882082 [No Abstract] [Full Text] [Related]
16. Use of combination chemotherapy with CCNU, bleomycin, and vincristine in the treatment of metastatic melanoma in patients resistant to DTIC therapy. Everall JD; Dowd PM Cancer Treat Rep; 1979 Jan; 63(1):151-5. PubMed ID: 84710 [No Abstract] [Full Text] [Related]
17. A randomized trial of adjuvant chemotherapy and immunotherapy in cutaneous melanoma. Veronesi U; Adamus J; Aubert C; Bajetta E; Beretta G; Bonadonna G; Bufalino R; Cascinelli N; Cocconi G; Durand J; De Marsillac J; Ikonopisov RL; Kiss B; Lejeune F; MacKie R; Madej G; Mulder H; Mechl Z; Milton GW; Morabito A; Peter H; Priario J; Paul E; Rumke P; Sertoli R; Tomin R N Engl J Med; 1982 Oct; 307(15):913-6. PubMed ID: 7050717 [TBL] [Abstract][Full Text] [Related]